Tags : Emblem S-ICD System

Boston Scientific Reports Results of Emblem S-ICD System in UNTOUCHED

Tuba Khan May 13, 2019

Shots: The UNTOUCHED study involves assessing Emblem Subcutaneous Implantable Defibrillator (S-ICD) system in 1,116 patients with a left ventricular ejection fraction (LVEF) ≤35% + ischemic heart disease The UNTOUCHED study […]readmore

Tags : Emblem S-ICD System

Boston Scientific Reports Results of Emblem S-ICD System in UNTOUCHED

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : Emblem S-ICD System

﻿Boston Scientific Reports Results of Emblem S-ICD System in UNTOUCHED

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company

Boston Scientific Reports Results of Emblem S-ICD System in UNTOUCHED